Brandenburg Kapital - News about Pentracor GmbH
Pentracor supports the fight against the virus COVID 19 through blood washing
Hennigsdorf - May 2021. Pentracor GmbH, a portfolio company of Brandenburg Kapital, produces and markets a specific adsorber for the therapeutic lowering of C-reactive protein (CRP) from the blood plasma of heart attack patients to reduce damage to the heart.
Since the beginning of the year, this technology has also been applied to individual COVID 19 patients with severe courses. The procedure can be used to filter the patient's blood. The C-reactive protein, which is suspected of causing severe inflammation, is filtered out. At Havelhöhe Hospital, CRP apheresis has already been successfully used in seven patients.
Brandenburg Kapital GmbH has been supporting the company since 2011.
Read the complete article here:
About Pentracor
Pentracor produces and markets a specific adsorber for the therapeutic lowering of C-reactive protein (CRP) from the blood plasma of heart attack patients to reduce damage to the heart. With CRP apheresis and the PentraSorb® filter product, it is pursuing a new approach in the acute treatment of heart attacks to minimize subsequent damage. Today, several hospitals in Germany are already successfully using CRP apheresis.
For more information, see www.brandenburg-kapital.de and www.pentracor.de